Kaya Holdings, Inc.
Kaya Holdings, Inc. (KAYS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
kays · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Kaya Holdings, Inc.You KAYS | $1M | N/A | — | — |
 Aion Therapeutic Inc. ANTCF | $2M | N/A | — | -$0.02 |
 Bhang Inc. BHNGF | $0M | N/A | — | -$0.02 |
 Bespoke Extracts, Inc. BSPK | $2M | N/A | — | -$0.10 |
 EVIO, Inc. EVIO | $2M | 3.34x | — | $0.00 |
 Hemp, Inc HEMP | $1M | N/A | — | -$0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Kaya Holdings, Inc. (KAYS) measures how much investors pay for each dollar of the company's trailing earnings. KAYS's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of —.
Frequently asked questions
KAYS pe ratio · 6 questionsKAYS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.01 and TTM EPS of —. Data sourced from Financial Modeling Prep via KAYS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Kaya Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09